Single-dose and steady-state pharmacokinetics of doxazosin given in combination with chlorothiazide to hypertensive subjects

Clin Pharmacokinet. 1989 Jun;16(6):387-91. doi: 10.2165/00003088-198916060-00004.

Abstract

The pharmacokinetics of doxazosin were determined in hypertensive subjects after a single dose of 1 mg, and at steady-state while receiving doses of 1, 2, 4 and 8 mg of the drug daily. Chlorothiazide 500 mg once daily was administered as additional therapy throughout the study. After a single dose doxazosin was rapidly absorbed, with peak plasma drug concentrations (Cmax) occurring after 2.1 +/- 0.4 hours. The elimination half-life in plasma was 10.7 +/- 1.2 hours. These parameters remained essentially unchanged during maintenance administration of doxazosin at each of the dose levels. Calculations of Cmax and area under the concentration-time curve (AUC0----infinity) indicated that the pharmacokinetic disposition of the drug remained linear over the dose range 1 to 8 mg.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antihypertensive Agents / adverse effects
  • Antihypertensive Agents / pharmacokinetics*
  • Antihypertensive Agents / therapeutic use
  • Blood Pressure / drug effects
  • Chlorothiazide / adverse effects
  • Chlorothiazide / pharmacokinetics*
  • Chlorothiazide / therapeutic use
  • Doxazosin
  • Female
  • Half-Life
  • Humans
  • Hypertension / drug therapy
  • Hypertension / metabolism*
  • Hypertension / physiopathology
  • Male
  • Middle Aged
  • Prazosin / adverse effects
  • Prazosin / analogs & derivatives*
  • Prazosin / pharmacokinetics
  • Prazosin / therapeutic use

Substances

  • Antihypertensive Agents
  • Chlorothiazide
  • Doxazosin
  • Prazosin